<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062971</url>
  </required_header>
  <id_info>
    <org_study_id>SOPHIA-PRO-122</org_study_id>
    <nct_id>NCT01062971</nct_id>
  </id_info>
  <brief_title>Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide</brief_title>
  <official_title>Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination of Timolol-Brimonidine-Dorzolamide In Patients With Open Angle Glaucoma Or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare intraocular pressure lowering effectiveness of a new fixed combination drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, double blind and prospective clinical study. We will include patients
      with confirmed diagnosis of primary open-angle glaucoma and/or ocular hypertension, with
      intraocular pressure (IOP) ranging between 21 and 31 mm Hg. Patients will be randomly divided
      into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2%
      dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the
      other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD
      Laboratories, USA). Patients will receive 1 drop twice a day of either formulations and were
      examined at days 2, 7, 15, 30, 60, and 90 after initiation of treatment. The primary
      objective is to compare the efficacy of both formulations, estimated as a decrease in IOP. A
      Goldmann applanation tonometer will be used for IOP determination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the intraocular pressure throughout the study period. To evaluate the reduction of intraocular pressure in both groups of treatment.</measure>
    <time_frame>basal, and days 1, 2,7,14,15, 30 and 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To follow and compare the safety parameters throughout the study period in both groups of treatment.</measure>
    <time_frame>basal, and day 1,2,7,15,30 y 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IOP Dorzolamide-Timolol-Brimonidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IOP dorzolamide-timolol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide-timolol-brimonidine</intervention_name>
    <description>Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Krytantek Ofteno</other_name>
    <other_name>Cosopt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects of either sex and any race with open-angle glaucoma or ocular
             hypertension;

          -  Visual acuity of 20/40 to 20/80 or better (Snellen equivalent).

        Exclusion Criteria:

          -  Clinically relevant ophthalmic or systemic conditions may be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo M Baiza-Duran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department. Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de la Visión. Hospital Universitario La Carlota. Universidad de Montemorelos</name>
      <address>
        <city>Montemorelos</city>
        <state>Nuevo Leon</state>
        <zip>67500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <name_title>Leopoldo Baiza-Duran</name_title>
    <organization>Laboratorios Sophia S.A de C.V.</organization>
  </responsible_party>
  <keyword>Open-angle glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>POAG</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 25, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

